Danaher Corporation DHR
Composite 47/100; the shares have moved about 35% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 29/100 — a moderate mark against it.
Balance-sheet strength ranks 70/100 — a moderate point in its favour.
Valuation ranks 29/100 — a moderate mark against it. Growth ranks 36/100 — a moderate mark against it. Income ranks 41/100 — a slight mark against it.
What the company does Danaher designs and markets professional, medical, research, and industrial products across Biotechnology, Life Sciences, and Diagnostics segments. Its offerings include lab filtration, mass spectrometers, flow cytometry, and cell culture media, serving therapeutic development and diagnostic workflows.
Key financials Gross margin 58.8%, operating margin 19.8%, net margin 16.0%. ROE 7.6%, ROA 4.0%, ROCE 6.0%. Revenue growth 2.9%, EPS growth -3.9%. Debt/Equity 0.53, net debt/EBITDA 2.93, interest coverage 17.31, current ratio 1.65.
Stock health Sideravia overall score 48.0 (Weak quality, richly valued). Strength 70.2, Valuation 30.2, Momentum 49.5, Income 40.8. Piotroski F-Score 6/9, Altman Z 3.43. Dividend yield 0.8%, payout 17.7%.
Price vs fair value The stock trades at a discount of 7.80% versus the analyst mean target of 227.96. - StockStory highlights Q2 research tools & consumables performance (Research Tools & Consumables Stocks Q2 Highlights: Danaher (NYSE:DHR)) - Simply Wall St. labels DHR stock as fairly valued amid a 23% five-year slide (Danaher (DHR) Stock Looks Fairly Valued On Its 23% Five Year Slide)
Looking forward Forward P/E 24.57, PEG 0.49. Analysts expect margin recovery alongside modest revenue growth of 2.9%. Momentum is positive over 3 months (26.88%) but lags 52-week high by 12.52%.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.